

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 October 2020 (15.10.2020)



(10) International Publication Number
WO 2020/210392 A1

- (51) International Patent Classification:
C07K 16/28 (2006.01) *C12N 5/0783* (2010.01)
- (21) International Application Number:
PCT/US2020/027320
- (22) International Filing Date:
08 April 2020 (08.04.2020)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/831,572 09 April 2019 (09.04.2019) US
19306261.9 02 October 2019 (02.10.2019) EP
- (71) Applicant: **SANOI** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR).
- (72) Inventor; and
(71) Applicant (for US only): **YANG, Zhi-Yong** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US).
- (72) Inventors: **BIRKENFELD, Joerg**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **NABEL, Gary J.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **QIU, Huawei**; 5 Primrose Lane, Westborough, Massachusetts 01581 (US). **REGULA, Joerg**; Innerkoflerstrasse 17 B, 81377 Munich (DE). **SEUNG, Edward**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **WEI, Ronnie**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **WU, Lan**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **XING, Zhen**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **XU,**

(54) Title: TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF




FIG. 1A

(57) Abstract: Provided herein are trispecific and/or tri valent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CDS polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

[Continued on next page]

Ling; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **PRADES, Catherine**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR). **DAB-DOUBI, Tarik**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR). **CAMERON, Béatrice**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR). **LEMOINE, Cendrine**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR).

(74) **Agent: JONES, Kevin** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
 — *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
 — *with sequence listing part of description (Rule 5.2(a))*